Open Orphan PLC - London-based pharmaceutical services contract research company - Says its Venn Life Sciences unit secures a contract renewal until the end of December 2021 from clinical-stage biopharmaceutical company Carna Biosciences Inc. Under the renewal, the Venn Life Sciences team will provide chemistry, manufacturing & control consultancy services for two of the Carna's leading development programmes.
"The extension of this contract further demonstrates our ability to collaborate successfully with our clients and provide a service that results in repeat business. Venn and Carna have built up a good working relationship over a period of several years where both parties closely collaborated on drug development planning and its execution through consultancy services contracts. We look forward to delivering this contract for Carna in the year ahead," said Open Orphan Chair Cathal Friel.
Current stock price: 23.72 pence
Year-to-date change: down 8.1%
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
